To investigate the brain receptor occupancy of idalopirdine in patients with Alzheimer's disease (AD)
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
3
Idalopirdine 60-120 mg daily dose
Johns Hopkins Hospital
Baltimore, Maryland, United States
5-HT6 Receptor Occupancy (RO)
RO in the region of interest will be calculated as 100 × (1 - BPND(treatment) / BPND(baseline)) where BPND is the binding potential
Time frame: Treatment day 10 (24 hours post dose)
Idalopirdine plasma concentration (CPET)
CPET is the concentration at the time of PET scan, defined as (CprePET + CpostPET) / 2 (average of the pre- and post-PET scanning measurements).
Time frame: Prior to and after PET scan on treatment day 10
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.